| Precigen, Inc. | |
| Industry: | Biotechnology |
| Traded As: | NASDAQ: Russell 2000 Component |
| Predecessors: | --> |
| Successors: | --> |
| Founders: | --> |
| Hq Location City: | Germantown, Maryland |
| Hq Location Country: | US |
| Areas Served: | --> |
| Owners: | --> |
| Num Employees: | 600 |
| Revenue: | $91 million (2019)[1] |
Precigen, Inc. (formerly Intrexon Corporation, NASDAQ: PGEN) is an American biotechnology company. Its president and CEO is Helen Sabzevari.
Intrexon was founded in 1998, and is headquartered in Germantown, Maryland.[2] [3] With a suite of proprietary and complementary technologies, Intrexon applies engineering to biological systems to enable DNA-based control over the function and output of living cells.[4]
In 2015, Intrexon purchased Oxitec, a maker of genetically sterile insects, for $160 million.[5] In April 2019, Intrexon formed a subsidiary called Precigen, with a focus on human gene therapy. Precigen went on to win orphan drug status from the FDA for a CAR-T based therapy (investigational drug name PRGN-3006) to treat acute myeloid leukemia.[6] [7] In early 2020, Intrexon adopted the name of its subsidiary, Precigen, and narrowed its focus to human gene editing.[8] [9] With the change in name the CEO of subsidiary Precigen, Helen Sabzevari, took over leadership of the company from Randal J. Kirk.[7]